How much does semaglutide actually cost
in 2026?

The six lanes you actually have

Forget the marketing pages. There are six legal pathways to GLP-1 weight loss in May 2026, and the prices range by an order of magnitude depending on which one fits your situation:

1. Brand-name Wegovy or Ozempic via insurance — cheapest if you can clear the prior-authorization hurdle
2. Compounded semaglutide via a licensed pharmacy — lowest cash-pay entry; still legal pending the FDA's proposed rule
3. NovoCare cash-pay — Novo Nordisk's direct self-pay program for Wegovy
4. LillyDirect Zepbound vials — switch molecule to tirzepatide; the cheapest brand-name cash-pay path
5. Telehealth + brand-name GLP-1 — licensed-clinician program prescribing branded medication
6. Brand-name Wegovy at list price — the option to avoid unless nothing else fits

We'll walk each one with the actual numbers. Skip ahead to the summary table if you want the comparison view first.

Lane 1: Wegovy or Ozempic via insurance

How to check fast: Call the member services number on the back of your insurance card. Ask specifically: "Is Wegovy on formulary? What's the prior authorization requirement? Is there a maximum quantity per fill?" Don't trust the formulary website — they're often out of date by months.

What it doesn't include: Most insurance plans require a documented BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity like high blood pressure or pre-diabetes) for Wegovy. Ozempic is covered for type 2 diabetes only. Prior authorization typically requires your prescriber to submit chart notes documenting prior weight-loss attempts (failed diet/exercise within 6 months). Expect the PA process to take 1–3 weeks the first time; renewals are faster.

Lane 2: Compounded semaglutide via a licensed pharmacy

The cash-pay lane that's been keeping GLP-1s accessible since 2022. Compounded semaglutide is made by U.S.-licensed compounding pharmacies under Section 503A or 503B of the Food, Drug, and Cosmetic Act. Compounded medications are not FDA-approved — they're prepared by licensed pharmacies under state regulation, not federal approval.

The FDA's April 30, 2026 proposed rule would close the 503B mass-compounding pathway if finalized. It is not yet final. Public comment runs through June 29, 2026; industry analysts expect the earliest implementation in Q3-Q4 2026. As of May 2026, compounded semaglutide remains legally available from licensed providers — and the 503A patient-specific pathway is not affected by the proposal regardless.

What compounded options don't include: the FDA's safety and effectiveness review that branded medications go through. Compounded products are formulated by licensed pharmacies under state regulation; they're not federally approved as safe and effective. The FDA has documented over 455 adverse-event reports tied to compounded semaglutide as of early 2025, many involving multidose-vial dosing errors. The risk profile is real but mostly tied to unlicensed gray-market sellers, not LegitScript-certified pharmacies like LegUpRx. Talk to your prescriber.

Lane 3: NovoCare cash-pay (Wegovy direct)

Lane 4: LillyDirect Zepbound vials (switching molecule)

Lane 5: Telehealth + brand-name GLP-1

Telehealth programs that prescribe branded medication (Wegovy, Ozempic, Mounjaro, Zepbound) and bundle clinical service into a monthly fee. All-in cost lands in the $450–$700/month range — manufacturer cash price plus a clinical-services fee. Worth it if you want brand-name FDA-approved medication, don't have an existing prescriber relationship, and value a single point of contact for the full program rather than coordinating across an insurance prescription + manufacturer cash program. Not worth it if your PCP will prescribe and you can route through NovoCare or LillyDirect directly.

Lane 6: Brand-name Wegovy at list price

The twelve-month all-in math, side by side

Three patterns to notice:

1. Insurance is the single biggest savings if available. The cost gap between a covered plan and any cash-pay option is $3,000–$5,000/year. Thirty minutes on the phone with your insurer is the highest-value single action you can take.
2. Compounded is roughly half the cost of branded cash-pay. $1,500–$3,600/year compounded vs $5,000–$6,000/year branded cash-pay. Whether the savings is worth the trade-off (no FDA approval, smaller safety dataset, regulatory uncertainty) is a decision for you and your prescriber.
3. Telehealth + brand-name is the most expensive bundle in most cases. Worth it if you value the bundled clinical service and don't have an existing prescriber. Not worth it if your PCP will prescribe and you can route through NovoCare or LillyDirect directly.

What the price doesn't include

Provider pages quote the medication price, but the all-in cost has more in it. Watch for these:

• Intake or consultation fees — some programs charge a separate $50–$150 one-time fee on top of the monthly price.
• Dose-escalation surcharges — the semaglutide titration ladder goes 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over months. Some programs raise the monthly price as the dose escalates; LegUpRx holds the price flat. Always ask.
• Shipping and cold-chain surcharges — injectable GLP-1s require refrigerated shipping. Most reputable programs include this; some surprise-bill for it.
• Side-effect-related lab tests — if you develop GI symptoms, fatigue, or other side effects, your prescriber may order labs. If your insurance doesn't cover these, expect $50–$200 per panel.
• Pause and cancellation fees — some subscription programs charge fees to pause or cancel. Read the fine print before committing to a 6-month plan.
• The cost of side effects you handle outside the program — OTC anti-nausea (ondansetron, ginger), fiber supplements, electrolyte drinks. Small money but real.

What we'd actually do

In order, lowest-effort-highest-leverage:

1. Spend 30 minutes calling your insurer. If Wegovy is covered with any plan-level path — even with prior-authorization hurdles — do this. The cost difference is $3,000–$5,000/year. We don't earn anything on this lane and we still tell you to do it first.
2. If insurance won't cover, start with LegUpRx's sublingual semaglutide at $174/month. Lowest legitimate cash entry point. LegitScript-certified. Survives the FDA's proposed rule under the 503A pathway.
3. If you want injectable, LegUpRx's injectable semaglutide w/ additives is $299/month (start the intake). Same pharmacy, same prescriber framework, injectable delivery.
4. For brand-name cash-pay, default to LillyDirect Zepbound vials at $349/month. Same drug class, similar or stronger outcomes than semaglutide. Lilly is the manufacturer — no markup layer. We don't earn anything on LillyDirect; we still recommend it.
5. Skip telehealth markups if you have a prescriber. Telehealth + brand-name is $450–$700/month, while NovoCare or LillyDirect with your existing PCP's prescription is $349–$499.
6. Avoid the list price. $1,349/month exists as a number on a price list, not as a sensible option.
7. Avoid "research peptide" sites and offshore vendors. The savings are real, the safety floor is gone. See our FDA-ban explainer.

Frequently asked questions

Sources

• Novo Nordisk — NovoCare Wegovy self-pay program (novocare.com)
• Eli Lilly — LillyDirect Zepbound vial program (lillydirect.com)
• Novo Nordisk WAC pricing — Wegovy list price, 2025
• New England Journal of Medicine — STEP-1 trial (2021) and 2-year extension data (2022)
• NEJM — SURMOUNT-5 (2024), tirzepatide vs semaglutide head-to-head
• U.S. Food and Drug Administration — Drug Shortages Database (semaglutide and tirzepatide status, 2024–2025)
• U.S. Food and Drug Administration — 503B bulks list proposed exclusion of semaglutide, tirzepatide, liraglutide (April 30, 2026)
• LegitScript pharmacy certification — LegUpRx (Leg Up Recovery) status

Prices change. We update this page when manufacturer programs adjust pricing or new lanes emerge.